Childhood diabetes mellitus: Recent advances & future prospects

Indian Journal of Medical Research

Volumn 125, Issue 3, 2007, Pages 231-250

  Dejkhamron, Prapai ^a   Menon, Ram K ^a   Sperling, Mark A ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Childhood diabetes; Glucose monitoring; Insulin therapy; MODY

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMYLIN; BCG VACCINE; BIGUANIDE DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN A; GAMMA INTERFERON; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LONG ACTING INSULIN; MANNITOL; METFORMIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; Q FEVER VACCINE; RAPAMYCIN; SODIUM CHLORIDE; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VITAMIN D;

ADJUVANT THERAPY; AUTOIMMUNITY; BLOOD GLUCOSE MONITORING; BRAIN EDEMA; CARBOHYDRATE METABOLISM; CELL DESTRUCTION; CELL ISOLATION; CELL PROLIFERATION; CHILD CARE; CHILD DEVELOPMENT; CHILD GROWTH; CHILD NUTRITION; CLINICAL TRIAL; CONTINUOUS INFUSION; CRANIOTOMY; DEVELOPING COUNTRY; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG STRUCTURE; EMBRYONIC STEM CELL; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GRAFT REJECTION; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; HYPOTHESIS; IMMUNOMODULATION; INCIDENCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN RESISTANCE; JUVENILE DIABETES MELLITUS; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; POPULATION RESEARCH; PROTEIN METABOLISM; REPEATED DRUG DOSE; REVIEW; SCREENING TEST; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WESTERN HEMISPHERE;

ADOLESCENT; AGE OF ONSET; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; INSULIN; MALE; PUBERTY;

EID: 34249288294     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl 1): S43-8.
2. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
3. Report of the Expert Committee on the Diagnosis and Classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
4. Sperling MA. Diabetes Mellitus. In: Sperling MA, editor. Pediatric endocrinology. 2nd ed. Philadelphia: Saunders; 2002. p. 323-66.
5. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 328: 750-4.
6. Ize-Ludlow D, Sperling MA. The classification of diabetes mellitus: a conceptual framework. Pediatr Clin North Am 2005; 52: 1533-52.
7. Barrett TG. Nonautoimmune forms of diabetes: Neonatal diabetes, DIDMOAAD-Wolfram, and related syndromes. In: Sperling MA, editor. Type 1 diabetes. Totowa: Humana Press; 2003 p. 163-82.
8. Porter JR, Barrett TG. Acquired non-type 1 diabetes in childhood: subtypes, diagnosis, and management. Arch Dis Child 2004; 89: 1138-44.
9. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology presentation, and management. Pediatr Clin North Am 2005; 52: 1553-78.
10. Kelly MA, Mijovic CH, Barnett AH. Genetics of type 1 diabetes. Best Pract Res Clin Endocrinol Metab 2001; 15: 279-91.
11. Kim MS, Polychronakos C. Immunogenetics of type 1 diabetes. Horm Res 2005; 64: 180-8.
12. Wraight PR, Fourlanos S, Morahan G, Harrison LC. Genetics of type 1 diabetes mellitus. In: Menon RK, Sperling MA, editors. Pediatrics diabetes. Norwell: Kluwer Academic Publishers; 2003 p. 1-28.
13. Pietropaolo M, Trucco M. Genetics of type 1 diabetes. In: Sperling MA, editor. Type 1 diabetes. Totowa: Humana Press; 2003 p. 55-70.
14. Pugliese A. Genetics of type 1 diabetes. Endocrinol Metab Clin North Am 2004; 33: 1-16.
15. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
16. Owerbach D, Pina L, Gabbay KH. A 212-kb region on chromosome 6q25 containing the TAB2 gene is associated with susceptibility to type 1 diabetes. Diabetes 2004; 53: 1890-3.
17. Xiao XH, Liu ZL, Wang H, Sun Q, Li WH, Yang GH, et al. Effects of vitamin D receptor gene polymorphisms on susceptibility to type 1 diabetes mellitus. Chin Med Sci J 2006; 21: 95-8.
18. Motohashi Y, Yamada S, Yanagawa T, Maruyama T, Suzuki R, Niino M, et al. Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 3137-40.
19. Chang TJ, Lei HH, Yeh JI, Chiu KC, Lee KC, Chen MC, et al. Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population. Clin Endocrinol (Oxf) 2000; 52: 575-80.
20. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat Genet 2004; 36: 337-8.
21. Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Pociot F, et al. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 2005; 54: 2995-3001.
22. Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in type 1 diabetes? Med Sci Monit 2005; 11: RA63-9.
23. Roivainen M. Enteroviruses: new findings on the role of enteroviruses in type 1 diabetes. Int J Biochem Cell Biol 2006; 38: 721-5.
24. Hyoty H. Environmental causes: viral causes. Endocrinol Metab Clin North Am 2004; 33: 27-44.
25. Lonnrot M, Hyoty H, Knip M, Roivainen M, Kulmala P, Leinikki P, et al. Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackievirus B4. Childhood Diabetes in Finland Study Group. Clin Exp Immunol 1996; 104: 398-405.
26. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 283-92.
27. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112: 352-63.
28. Devendra D, Eisenbarth GS. Interferon alpha - a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004; 111: 225-33.
29. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002; 115: 18-29.
30. Chowdhury TA, Mijovic CH, Barnett AH. The aetiology of type I diabetes. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 181-95.
31. Mrena S, Virtanen SM, Laippala P, Kulmala P, Hannila ML, Akerblom HK, et al. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006; 29: 662-7.
32. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999; 84: 4371-8.
33. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001; 44: 914-22.
34. Dabelea D, D'Agostino RB, Jr., Mayer-Davis EJ, Pettitt DJ, Imperatore G, Dolan LM, et al. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 2006; 29: 290-4.
35. Kordonouri O, Hartmann R. Higher body weight is associated with earlier onset of Type 1 diabetes in children: confirming the 'Accelerator Hypothesis'. Diabet Med 2005; 22: 1783-4.
36. Knerr I, Wolf J, Reinehr T, Stachow R, Grabert M, Schober E, et al. The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 2005; 48: 2501-4.
37. von Muhlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med 1995; 333: 704-8.
38. Sperling MA. Neonatal diabetes mellitus: from understudy to center stage. Curr Opin Pediatr 2005; 17: 512-8.
39. Sperling MA. ATP-sensitive potassium channels -neonatal diabetes mellitus and beyond. N Engl J Med 2006; 355: 507-10.
40. Sperling MA. Neonatal diabetes. In: Menon RK, Sperling MA, editors. Pediatric diabetes. Norwell: Kluwer acedemic publishers; 2003 p. 215-25.
41. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006; 15: 1793-800.
42. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann. R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355: 456-66.
43. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467-77.
44. Haider S, Antcliff JF, Proks P, Sansom MS, Ashcroft FM. Focus on Kir6.2: a key component of the ATP-sensitive potassium channel. J Mol Cell Cardiol 2005; 38: 927-36.
45. Metz C, Cave H, Bertrand AM, Deffert C, Gueguen-Giroux B, Czernichow P, et al. Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. J Pediatr 2002; 141: 483-9.
46. Gragnoli C, Stanojevic V, Gorini A, Von Preussenthal GM, Thomas MK, Habener JF. IPF-1/MODY4 gene missense mutation in an Italian family with type 2 and gestational diabetes. Metabolism 2005; 54: 983-8.
47. Rissanen J, Markkanen A, Karkkainen P, Pihlajamaki J, Kekalainen P, Mykkanen L, et al. Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. Diabetes Care 2000; 23: 70-3.
48. Trajkovski M, Mziaut H, Schwarz PE, Solimena M. Genes of type 2 diabetes in beta cells. Endocrinol Metab Clin North Am 2006; 35: 357-69.
49. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52: 568-72.
50. Katagiri H, Asano T, Ishihara H, Inukai K, Anai M, Miyazaki J, et al. Nonsense mutation of glucokinase gene in late-onset non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 1316-7.
51. Giuffrida FM, Reis AF. Genetic and clinical characteristics of maturity-onset diabetes of the young. Diabetes Obes Metab 2005; 7: 318-26.
52. Owen K, Hattersley AT. Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab 2001; 15: 309-23.
53. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-80.
54. Velho G, Robert JJ. Maturity-onset diabetes of the young (MODY): genetic and clinical characteristics. Horm Res 2002; 57 (Suppl 1): 29-33.
55. Gloyn AL, Odili S, Zelent D, Buettger C, Castleden HA, Steele AM, et al. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young. J Biol Chem 2005; 280: 14105-13.
56. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15: 106-10.
57. Njolstad PR, Sagen JV, Bjorkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes 2003; 52: 2854-60.
58. Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001; 344:1588-92.
59. Agus MS, Wolfsdorf JI. Diabetic ketoacidosis in children. Pediatr Clin North Am 2005; 52: 1147-63.
60. Menon RK, Sperling MA. Diabetic Ketoacidosis. In: Sperling MA, editor. Type 1 diabetes. Totowa: Humana Press; 2003 p. 183-98.
61. Menon RK, Sperling MA. Diabetic ketoacidosis. In: Menon RK, Sperling MA, editors. Pediatric diabetes. Norwell: Kluwer Acedemic Publishers; 2003 p. 227-42.
62. Wolfsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29: 1150-9.
63. Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics 2004; 113: e133-40.
64. Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89: 188-94.
65. Sperling MA. Cerebral edema in diabetic ketoacidosis: an underestimated complication? Pediatr Diabetes 2006; 7: 73-4.
66. Glaser NS, Wootton-Gorges SL, Buonocore MH, Marcin JP, Rewers A, Strain J, et al. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes 2006; 7: 75-80.
67. Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr 2005; 146: 688-92.
68. Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001; 344: 264-9.
69. Puliyel JM. Osmotonicity of acetoacetate: possible implications for cerebral edema in diabetic ketoacidosis. Med Sci Monit 2003; 9: BR130-3.
70. Figueroa RE, Hoffman WH, Momin Z, Pancholy A, Passmore GG, Allison J. Study of subclinical cerebral edema in diabetic ketoacidosis by magnetic resonance imaging T2 relaxometry and apparent diffusion coefficient maps. Endocr Res 2005; 31: 345-55.
71. Glaser NS, Wootton-Gorges SL, Marcin JP, Buonocore MH, Dicarlo J, Neely EK, et al. Mechanism of cerebral edema in children with diabetic ketoacidosis. J Pediatr 2004; 145: 164-71.
72. Mahoney CP, Vlcek BW, DelAguila M. Risk factors for developing brain herniation during diabetic ketoacidosis. Pediatr Neurol 1999; 21: 721-7.
73. Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 2004; 27: 1541-6.
74. Curtis JR, Bohn D, Daneman D. Use of hypertonic saline in the treatment of cerebral edema in diabetic ketoacidosis (DKA). Pediatr Diabetes 2001; 2: 191-4.
75. The writing team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes melllitus on development and progression of diabetic nephropathy. The epidemiology of diabetes intervention and comlications (EDIC) study. JAMA 2003; 290: 2159-67.
76. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
77. White NH. The DCCT and its implications for management of diabetes in children and adolescents. In: Menon RK, editor. Pediatric diabetes. Norwell: Kluwer Acedemic Publisher; 2003 p. 337-69.
78. Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Pediatr Clin North Am 2005; 52: 1705-33.
79. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212.
80. Sieg A, Guy RH, Delgado-Charro MB. Noninvasive and minimally invasive methods for transdermal glucose monitoring. Diabetes Technol Ther 2005; 7: 174-97.
81. Klonoff DC. A review of continuous glucose monitoring technology. Diabetes Technol Ther 2005; 7: 770-5.
82. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006; 23: 1-12.
83. Rungby J, Brock B, Schmitz O. New strategies in insulin treatment: analogues and noninvasive routes of administration. Fundam Clin Pharmacol 2005; 19: 127-32.
84. Rachmiel M, Perlman K, Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 2005; 52: 1651-75.
85. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-83.
86. Gomez-Perez FJ, Rull JA. Insulin therapy: current alternatives. Arch Med Res 2005; 36: 258-72.
87. Goldman-Levine JD, Lee KW. Insulin detemir- a new basal insulin analog. Ann Pharmacother 2005; 39: 502-7.
88. Williams RM, Dunger DB. Insulin treatment in children and adolescents. Acta Paediatr 2004; 93: 440-6.
89. Tamborlane WV, Fredrickson LP, Ahern JH. Insulin pump therapy in childhood diabetes mellitus: guidelines for use. Treat Endocrinol 2003; 2: 11-21.
90. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18 (Suppl 1): S14-20.
91. Renard E. Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? Diabetes Metab 2005; 31: 4S40-44.
92. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003; 112: 559-64.
93. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-8.
94. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20: 886-98.
95. Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother 2005; 39: 843-53.
96. Urakami T, Morimoto S, Owada M, Harada K. Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int 2005; 47: 430-3.
97. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003; 26: 138-43.
98. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53 (Suppl 3): S233-8.
99. Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16: 228-32.
100. Balamurugan AN, Bottino R, Giannoukakis N, Smetanka C. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006; 32: 231-43.
101. Bottino R, Trucco M, Balamurugan AN, Starzl TE. Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol 2002; 16: 457-74.
102. Nanji SA, Shapiro AM. Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab 2006; 8: 15-25.
103. Street CN, Sipione S, Helms L, Binette T, Rajotte RV, Bleackley RC, et al. Stem cell-based approaches to solving the problem of tissue supply for islet transplantation in type 1 diabetes. Int J Biochem Cell Biol 2004; 36: 667-83.
104. Schatz DA, Atkinson MA. Islet cell autoantibodies: a case of a premature obituary. Pediatr Diabetes 2005; 6: 181-3.
105. Kulmala P, Savola K, Petersen JS, Vahasalo P, Karjalainen J, Lopponen T, et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998; 101: 327-36.
106. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103-8.
107. LaGasse JM, Brantley MS, Leech NJ, Rowe RE, Monks S, Palmer JP, et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002; 25: 505-11.
108. Vendrame F, Gottlieb PA. Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am 2004; 33: 75-92.
109. Virtanen SM, Saukkonen T, Savilahti E, Ylonen K, Rasanen L, Aro A, et al. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. Diabetologia 1994; 37: 381-7.
110. Virtanen SM, Laara E, Hypponen E, Reijonen H, Rasanen L, Aro A, et al. Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Childhood diabetes in Finland study group. Diabetes 2000; 49: 912-7.
111. Wilson DM, Buckingham B. Prevention of type 1a diabetes mellitus. Pediatr Diabetes 2001; 2: 17-24.
112. Aly T, Devendra. D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 2005; 12: 481-90.
113. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 1996; 19: 1357-63.
114. Elliott RB, Pilcher CC, Fergusson DM, Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996; 9: 501-9.
115. Vague P, Vialettes B, Lassmann-Vague V, Vallo JJ. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1987; i: 619-20.
116. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 358: 925-31.
117. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005; 16: 261-6.
118. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-3.
119. Maniatis AK, Eisenbarth GS. Prediction and prevention of type 1 diabetes. In: Sperling MA, editor. Type 1 diabetes. Totowa: Humana Press; 2003 p. 55-70.